26/05/2015 : THERADIAG RECEIVES FROST & SULLIVAN 2015 EUROPEAN THERANOSTICS PRODUCT LEADERSHIP AWARD

Croissy-Beaubourg and Montpellier, May 26, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that is has been awarded  the Frost & Sullivan 2015 European Theranostics Product…

Continue Reading26/05/2015 : THERADIAG RECEIVES FROST & SULLIVAN 2015 EUROPEAN THERANOSTICS PRODUCT LEADERSHIP AWARD

20/05/2015 : THERADIAG AND HOSPIRA SIGN A PARTNERSHIP AGREEMENT

Hospira to provide Theradiag’s LISA TRACKER infliximab monitoring kits jointly with biosimilar Inflectra® in Europe, Canada and Australia   Croissy-Beaubourg and Montpellier, May 20, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics…

Continue Reading20/05/2015 : THERADIAG AND HOSPIRA SIGN A PARTNERSHIP AGREEMENT

11/05/2015 : THERADIAG LAUNCHES LISA TRACKER IN CANADA

Exclusive partnership agreement with Somagen Diagnostics Inc.First North American market penetration for LISA TRACKERPositive recommendation by Canadian health authorities on biotherapy monitoring Croissy-Beaubourg and Montpellier, May 11, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing…

Continue Reading11/05/2015 : THERADIAG LAUNCHES LISA TRACKER IN CANADA